HUP0100939A2 - Spiropiperidinszármazékok, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk - Google Patents
Spiropiperidinszármazékok, ezeket tartalmazó gyógyszerkészítmények és alkalmazásukInfo
- Publication number
- HUP0100939A2 HUP0100939A2 HU0100939A HUP0100939A HUP0100939A2 HU P0100939 A2 HUP0100939 A2 HU P0100939A2 HU 0100939 A HU0100939 A HU 0100939A HU P0100939 A HUP0100939 A HU P0100939A HU P0100939 A2 HUP0100939 A2 HU P0100939A2
- Authority
- HU
- Hungary
- Prior art keywords
- group
- groups
- substituted
- substituents
- substituent group
- Prior art date
Links
- JUXAVSAMVBLDKO-UHFFFAOYSA-N 1-(1-azabicyclo[2.2.2]octan-3-yl)-3-[3-(1h-indol-3-yl)-1-oxo-1-spiro[1,2-dihydroindene-3,4'-piperidine]-1'-ylpropan-2-yl]urea Chemical class C1N(CC2)CCC2C1NC(=O)NC(C(=O)N1CCC2(C3=CC=CC=C3CC2)CC1)CC1=CNC2=CC=CC=C12 JUXAVSAMVBLDKO-UHFFFAOYSA-N 0.000 title abstract 3
- 239000003814 drug Substances 0.000 title 1
- 125000001424 substituent group Chemical group 0.000 abstract 18
- 125000003118 aryl group Chemical group 0.000 abstract 5
- 125000001072 heteroaryl group Chemical group 0.000 abstract 4
- 125000001931 aliphatic group Chemical group 0.000 abstract 3
- 125000000217 alkyl group Chemical group 0.000 abstract 3
- 125000004450 alkenylene group Chemical group 0.000 abstract 2
- 125000002947 alkylene group Chemical group 0.000 abstract 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 2
- 125000000392 cycloalkenyl group Chemical group 0.000 abstract 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 2
- 125000004043 oxo group Chemical group O=* 0.000 abstract 2
- 206010020751 Hypersensitivity Diseases 0.000 abstract 1
- 102000007124 Tachykinin Receptors Human genes 0.000 abstract 1
- 108010072901 Tachykinin Receptors Proteins 0.000 abstract 1
- 206010046543 Urinary incontinence Diseases 0.000 abstract 1
- 125000002252 acyl group Chemical group 0.000 abstract 1
- 125000004442 acylamino group Chemical group 0.000 abstract 1
- 125000003545 alkoxy group Chemical group 0.000 abstract 1
- 125000004453 alkoxycarbonyl group Chemical group 0.000 abstract 1
- 208000026935 allergic disease Diseases 0.000 abstract 1
- 230000007815 allergy Effects 0.000 abstract 1
- 125000003277 amino group Chemical group 0.000 abstract 1
- 230000003042 antagnostic effect Effects 0.000 abstract 1
- 125000003710 aryl alkyl group Chemical group 0.000 abstract 1
- 208000006673 asthma Diseases 0.000 abstract 1
- 206010006451 bronchitis Diseases 0.000 abstract 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 1
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 1
- 125000001188 haloalkyl group Chemical group 0.000 abstract 1
- 125000005843 halogen group Chemical group 0.000 abstract 1
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 abstract 1
- 229910052757 nitrogen Inorganic materials 0.000 abstract 1
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 1
- 125000004430 oxygen atom Chemical group O* 0.000 abstract 1
- 239000000825 pharmaceutical preparation Substances 0.000 abstract 1
- 206010039083 rhinitis Diseases 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 abstract 1
- 229910052717 sulfur Inorganic materials 0.000 abstract 1
- 125000004434 sulfur atom Chemical group 0.000 abstract 1
- 125000003396 thiol group Chemical group [H]S* 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/428—Thiazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/73—Unsubstituted amino or imino radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
- C07D277/62—Benzothiazoles
- C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D307/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
- C07D333/54—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
- C07D333/60—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Pulmonology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Hydrogenated Pyridines (AREA)
Abstract
A találmány új spiropiperidin-származékokra vonatkozik, amelyekantagonista hatásúak tachykinin-receptorokkal (NK1, NK3 és NK3)szemben. A találmány szerinti spiropiperidin-származékok (I) általánosképletében R1 és R2 azonos vagy eltérő jelentéssel arilcsoportot,heteroarilcsoportot, az A szubsztituenscsoportból megválasztott 1-3helyettesítővel szubsztituált arilcsoportot vagy az Aszubsztituenscsoportból megválasztott 1-3 helyettesítővelszubsztituált heteroarilcsoportot jelent; A jelentése metiléncsoport,karbonilcsoport vagy szulfonilcsoport, B jelentése egyszeres kémiaikötés, alkilén- vagy alkeniléncsoport; D jelentése oxigénatom vagykénatom; E jelentése alkiléncsoport vagy alkeniléncsoport; a (IV)általános képletű csoport (V) vagy (VI) általános képletű csoportotjelent, és ezekben G jelentése cikloalkéngyűrű, a Bszubsztituenscsoportból megválasztott egy vagy két helyettesítővelszubsztituált cikloalkángyűrű vagy a B szubsztituenscsoportbólmegválasztott egy vagy kettő helyettesítővel szubsztituáltcikloalkéngyűrű; Ar jelentése arilgyűrű, heteroarilgyűrű, az Aszubsztituenscsoportból megválasztott 1-3 helyettesítővelszubsztituált arilgyűrű vagy A szubsztituenscsoportból megválasztott1-3 helyettesítővel szubsztituált heteroarilgyűrű; R3 jelentése rövidszénláncú alkilcsoport; és n értéke 1, 2 vagy 2; azzal a megkötéssel,hogy G jelentése egyetlen oxocsoporttal szubsztituált csoporttóleltérő; az A szubsztituenscsoport a következő szubsztituensekből áll:halogénatomok, alkilcsoportok, halogénalkilcsoportok, alkoxicsoportok,alkoxikarbonilcsoportok, karboxilcsoportok, hidroxilcsoportok, alifásacilcsoportok, alifás acilaminocsoportok, aminocsoportok éscianocsoportok; a B szubsztituenscsoport a következőszubsztituensekből áll: oxocsoportok, hidroxilcsoportok,karboxilcsoportok és tiolcsoportok; továbbá a nitrogénatomon lévőszubsztituensként alkil-, aril-, aralkil-, alifás acilésalkánszulfonilcsoportok, amelyek mindegyike helyettesítve lehet az Aszubsztituenscsoportból megválasztott helyettesítővel. A találmánykiterjed a vegyületeket tartalmazó gyógyszerkészítményekre és ezekalkalmazására asztma és/vagy bronhitisz, rhinitisz, allergia ésvizeletvisszatartási elégtelenség kezelésére. Ó
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP1111298 | 1998-01-23 | ||
| JP13295998 | 1998-05-15 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| HUP0100939A2 true HUP0100939A2 (hu) | 2002-05-29 |
| HUP0100939A3 HUP0100939A3 (en) | 2002-06-28 |
Family
ID=26346503
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HU0100939A HUP0100939A3 (en) | 1998-01-23 | 1999-01-22 | Spiropiperidine derivatives, medicaments containing them and their use |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US6511975B1 (hu) |
| EP (1) | EP1057827B1 (hu) |
| KR (1) | KR100629672B1 (hu) |
| CN (1) | CN1165533C (hu) |
| AT (1) | ATE249455T1 (hu) |
| AU (1) | AU741924B2 (hu) |
| BR (1) | BR9907173A (hu) |
| CA (1) | CA2318361A1 (hu) |
| DE (1) | DE69911176T2 (hu) |
| DK (1) | DK1057827T3 (hu) |
| ES (1) | ES2203061T3 (hu) |
| HK (1) | HK1032780A1 (hu) |
| HU (1) | HUP0100939A3 (hu) |
| ID (1) | ID25477A (hu) |
| IL (1) | IL137295A (hu) |
| MX (1) | MXPA00007240A (hu) |
| NO (1) | NO317979B1 (hu) |
| NZ (1) | NZ505599A (hu) |
| PT (1) | PT1057827E (hu) |
| TR (1) | TR200002072T2 (hu) |
| WO (1) | WO1999037642A1 (hu) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005080339A1 (ja) * | 2004-02-25 | 2005-09-01 | Sankyo Company, Limited | スルホニルオキシ誘導体 |
| KR20060127157A (ko) | 2004-02-25 | 2006-12-11 | 상꾜 가부시키가이샤 | 인다놀 유도체 |
| EA014239B1 (ru) * | 2005-03-08 | 2010-10-29 | Янссен Фармацевтика Н.В. | Производные диаза-спиро-[4,4]нонана в качестве антагонистов нейрокинина (nk1) |
| US8224647B2 (en) | 2005-10-03 | 2012-07-17 | Nuance Communications, Inc. | Text-to-speech user's voice cooperative server for instant messaging clients |
| PT2913326T (pt) | 2008-05-14 | 2020-08-24 | Scripps Research Inst | Novos moduladores de recetores de fosfato de esfingosina |
| MX2011009700A (es) | 2009-03-17 | 2011-12-08 | Daiichi Sankyo Co Ltd | Derivado de amida. |
| MY189750A (en) * | 2009-11-13 | 2022-03-02 | Receptos Llc | Selective sphingosine 1 phosphate receptor modulators and methods of chiral synthesis |
| AU2010319982B2 (en) * | 2009-11-13 | 2016-02-04 | Receptos Llc | Selective heterocyclic sphingosine 1 phosphate receptor modulators |
| MY160907A (en) * | 2009-11-13 | 2017-03-31 | Receptos Inc | Sphingosine 1 phosphate receptor modulators and methods of chiral synthesis |
| EP2484674A1 (en) * | 2011-02-02 | 2012-08-08 | Rottapharm S.P.A. | Spiro aminic compounds with NK1 antagonist activity |
| WO2012158550A2 (en) | 2011-05-13 | 2012-11-22 | Receptos, Inc. | Selective heterocyclic sphingosine 1 phosphate receptor modulators |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2119174T3 (es) * | 1993-01-28 | 1998-10-01 | Merck & Co Inc | Azaciclos espiro-sustituidos como antagonistas de los receptores de las taquiquininas. |
| RU2135494C1 (ru) | 1995-12-01 | 1999-08-27 | Санкио Компани Лимитед | Гетероциклические соединения и композиция на их основе, проявляющая антагонистическое действие в отношении рецепторов тахикинина |
| JP3192631B2 (ja) * | 1997-05-28 | 2001-07-30 | 三共株式会社 | 飽和複素環化合物からなる医薬 |
| PT987269E (pt) * | 1997-05-30 | 2003-11-28 | Sankyo Co | Sais de derivados sulfoxido opticamente activo |
-
1999
- 1999-01-22 ES ES99901134T patent/ES2203061T3/es not_active Expired - Lifetime
- 1999-01-22 KR KR1020007007983A patent/KR100629672B1/ko not_active IP Right Cessation
- 1999-01-22 DE DE69911176T patent/DE69911176T2/de not_active Expired - Fee Related
- 1999-01-22 AU AU20739/99A patent/AU741924B2/en not_active Ceased
- 1999-01-22 TR TR2000/02072T patent/TR200002072T2/xx unknown
- 1999-01-22 WO PCT/JP1999/000226 patent/WO1999037642A1/ja not_active Application Discontinuation
- 1999-01-22 ID IDW20001358A patent/ID25477A/id unknown
- 1999-01-22 IL IL13729599A patent/IL137295A/en active IP Right Grant
- 1999-01-22 NZ NZ505599A patent/NZ505599A/xx unknown
- 1999-01-22 AT AT99901134T patent/ATE249455T1/de not_active IP Right Cessation
- 1999-01-22 CA CA002318361A patent/CA2318361A1/en not_active Abandoned
- 1999-01-22 PT PT99901134T patent/PT1057827E/pt unknown
- 1999-01-22 CN CNB998044369A patent/CN1165533C/zh not_active Expired - Fee Related
- 1999-01-22 BR BR9907173-8A patent/BR9907173A/pt not_active Application Discontinuation
- 1999-01-22 HU HU0100939A patent/HUP0100939A3/hu unknown
- 1999-01-22 EP EP99901134A patent/EP1057827B1/en not_active Expired - Lifetime
- 1999-01-22 MX MXPA00007240A patent/MXPA00007240A/es not_active IP Right Cessation
- 1999-01-22 DK DK99901134T patent/DK1057827T3/da active
-
2000
- 2000-07-13 US US09/616,092 patent/US6511975B1/en not_active Expired - Fee Related
- 2000-07-14 NO NO20003630A patent/NO317979B1/no unknown
-
2001
- 2001-05-08 HK HK01103216A patent/HK1032780A1/xx not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| WO1999037642A1 (en) | 1999-07-29 |
| AU741924B2 (en) | 2001-12-13 |
| EP1057827A4 (en) | 2001-11-21 |
| EP1057827A1 (en) | 2000-12-06 |
| NO20003630D0 (no) | 2000-07-14 |
| DE69911176D1 (de) | 2003-10-16 |
| BR9907173A (pt) | 2000-10-10 |
| DK1057827T3 (da) | 2004-01-26 |
| HUP0100939A3 (en) | 2002-06-28 |
| AU2073999A (en) | 1999-08-09 |
| KR100629672B1 (ko) | 2006-09-29 |
| PT1057827E (pt) | 2003-11-28 |
| IL137295A0 (en) | 2001-07-24 |
| NO20003630L (no) | 2000-09-20 |
| ATE249455T1 (de) | 2003-09-15 |
| KR20010034280A (ko) | 2001-04-25 |
| ES2203061T3 (es) | 2004-04-01 |
| US6511975B1 (en) | 2003-01-28 |
| HK1032780A1 (en) | 2001-08-03 |
| CA2318361A1 (en) | 1999-07-29 |
| EP1057827B1 (en) | 2003-09-10 |
| CN1294588A (zh) | 2001-05-09 |
| NZ505599A (en) | 2003-06-30 |
| CN1165533C (zh) | 2004-09-08 |
| ID25477A (id) | 2000-10-05 |
| DE69911176T2 (de) | 2004-06-24 |
| NO317979B1 (no) | 2005-01-17 |
| MXPA00007240A (es) | 2002-05-08 |
| TR200002072T2 (tr) | 2000-12-21 |
| IL137295A (en) | 2005-12-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HUP0300138A2 (en) | Cyclic amine derivatives as ccr5 antagonists, their production and use and pharmaceutical compositions containing them | |
| AR012315A1 (es) | Derivados de ditiolan y el uso de los mismos en la fabricacion de un medicamento. | |
| WO1999033858A3 (en) | Estrone sulfamate inhibitors of estrone sulfatase, and associated pharmaceutical compositions and methods of use | |
| ATE402174T1 (de) | Imidazopyridinderivate als kinaseinhibitoren | |
| WO2003062259A3 (en) | Non-aromatic 17.alpha.-esters of androstane-17.beta.-carboxylate esters as anti-inflammatory agents | |
| CO5580768A2 (es) | Derivados de 4,5-diariltiazol como ligandos cb-1 | |
| BR9815377A (pt) | Derivados de sulfonil | |
| DE60043349D1 (de) | Chinazolin-derivate und ihre verwendung als arzneimittel | |
| HUP0301722A2 (hu) | Pirimidinszármazékok, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk | |
| HUP0204474A2 (hu) | 1H-imidazopiridin-származékok, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk | |
| AR004219A1 (es) | Nuevos derivados de quinazolina, procedimientos para su preparacion, composiciones que los contienen y su uso en la preparacion de medicamentos,particularmente en el tratamiento de trastornos inflamatorios | |
| HUP0001154A2 (hu) | 3-Piperidil-4-oxo-kinazolin-származékok és a vegyületeket tartalmazó gyógyászati készítmények | |
| HUP0400246A2 (hu) | 1,2,4-Trioxolánt tartalmazó maláriaellenes gyógyszerkészítmények és eljárás az előállításukra és az alkalmazásukra | |
| HUP0104188A2 (hu) | Antranilsav- és tioantranilsav-N-aril-amidok, előállításuk és alkalmazásuk VEGF receptor tirozinkináz inhibítorokként | |
| HUP0004529A2 (hu) | VLA-4 által mediált leukocita adhéziót gátló szulfonilezett dipeptid-származékok, ezeket tartalmazó gyógyászati készítmények, valamint alkalmazásuk | |
| NO905572L (no) | Fremgangsmaate for fremstilling av peptidforbindelser. | |
| HUP0103165A2 (hu) | Tiazolinsavszármazékok, a vegyületeket tartalmazó gyógyászati készítmények és alkalmazásuk | |
| BR0211427A (pt) | Compostos, processo para preparar os mesmos, composição adequada para combater fungos danosos, uso de compostos, e, processo para combater fungos danosos | |
| MY119238A (en) | 8-quinolinzanthine and 8-isoquinolinxanthine derivatives as pde 5 inhibitors | |
| HUP0100939A2 (hu) | Spiropiperidinszármazékok, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk | |
| HUP9904363A2 (hu) | Muszkarin antagonista piperidin-éterek és az ezeket tartalmazó gyógyszerkészítmények | |
| HUP0002839A2 (hu) | Pirrolo[3,4-d]pirimidinon-származékok, alkalmazásuk, az ezeket tartalmazó gyógyszerkészítmények, eljárás előállításukra | |
| HUP0402378A2 (hu) | Gyulladáskeltő citokinokat gátló spirociklikus 6,7-dihidro-5H-pirazolo[1,2-a]pirazol-1-onok és az ezeket tartalmazó gyógyszerkészítmények | |
| DK0790248T3 (da) | 3-Aza-piperidon-(tetrahydropyrimidin-2-on)- og 3-oxa-piperidon-(1,3-oxazin-2-on)-derivater, deres fremstilling og deres anvendelse som tachykinin/neurokinin-antagonister | |
| CA2280730A1 (en) | Substituted (1,3-bis(cyclohexylmethyl)-1,2,3,6-tetrahydro-2,6-dioxo-9h-purin-8-yl)phenyl derivatives, their preparation and their use in the treatment of inflammatory conditions and immune disorders |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FD9A | Lapse of provisional protection due to non-payment of fees |